Gadobutrol (Gadavist, Gadovist, BAY86-4875)
Sponsors
Bayer
Conditions
Brain MetastasesBreast CancerCentral Nervous System DiseasesCoronary Artery DiseaseDiagnostic ImagingMagnetic Resonance ImagingVascular Diseases
Phase 1
Phase 3
Efficacy and Safety Study to Evaluate Gadavist (Gadobutrol) as Contrast Agent in Magnetic Resonance Imaging (MRI) of Brain or Spine Diseases in Chinese Patients
CompletedNCT00395460
Start: 2006-09-30End: 2007-04-30Updated: 2015-06-08
Efficacy and Safety Study to Evaluate Gadavist (Gadobutrol) as Contrast Agent in Magnetic Resonance Imaging (MRI) of Vascular Diseases in Chinese Patients
CompletedNCT00395733
Start: 2006-10-31End: 2007-10-31Updated: 2013-12-18
SH L 562BB Phase II/III Dose Justification and Gadoteridol-controlled Comparative Study
CompletedNCT00522951
Start: 2007-08-31End: 2008-08-31Updated: 2017-08-28
Safety and Efficacy of Gadobutrol 1.0 Molar ( Gadavist ) in Patients for Central Nervous System (CNS) Imaging
CompletedNCT00623467
Start: 2007-12-31End: 2008-12-31Updated: 2014-02-10
Safety and Efficacy of Gadobutrol 1.0 Molar (Gadavist) in Patients for Central Nervous System (CNS) Imaging
CompletedNCT00709852
Start: 2008-06-30End: 2009-04-30Updated: 2014-12-30
Efficacy and Safety of Gadobutrol 1.0 Molar (Gadovist) for Breast MRI
CompletedNCT01067976
Start: 2010-02-28End: 2012-01-31Updated: 2014-11-11
Efficacy and Safety of Gadobutrol 1.0 Molar (Gadovist) for Breast Magnetic Resonance Imaging (MRI)
CompletedNCT01104584
Start: 2010-05-31End: 2012-01-31Updated: 2014-11-11
Gadobutrol / Gadavist-enhanced Cardiac Magnetic Resonance Imaging (CMRI) to Detect Coronary Artery Disease (CAD)
CompletedNCT01890434
Start: 2013-08-26End: 2016-11-10Updated: 2019-07-31